Rafael A Meneguz-Moreno1,2, J Ribamar Costa1, Alexandre Abizaid3,4. 1. Department of Interventional Cardiology, Instituto Dante Pazzanese de Cardiologia, Av. Dr. Dante Pazzanese, 500 - Vila Mariana, São Paulo, SP, 04012-180, Brazil. 2. Department of Medicine, Universidade Federal de Sergipe, Aracaju, Sergipe, Brazil. 3. Department of Interventional Cardiology, Instituto Dante Pazzanese de Cardiologia, Av. Dr. Dante Pazzanese, 500 - Vila Mariana, São Paulo, SP, 04012-180, Brazil. aabizaid@uol.com.br. 4. Hospital Sírio Libanês, São Paulo, Brazil. aabizaid@uol.com.br.
Abstract
PURPOSE OF REVIEW: The present manuscript reviews the mechanism of action of drug-coated balloons (DCBs), offering a brief summary of the main clinical evidence on these devices. RECENT FINDINGS: DCBs are regular semi-compliant balloons coated with antiproliferative agents that are rapidly released on contact with the vessel intima, exerting an anti-restenotic effect. This technology may offer some benefits of drug-eluting stents, in particular for the treatment of restenotic lesions, small vessels, and in patients at high-bleeding risk, when the prolonged dual antiplatelet regimen should be avoided. Most recent data have pointed to a possible benefit of these devices in treating bare metal stents (BMS) or drug-eluting stents in-stent restenosis (DES ISR), effectively reducing the recurrence of restenosis and avoiding additional layers of metal in the same coronary segment. In other clinical scenarios such as bifurcations, small vessels, and de novo lesions, data is more scarce and the benefits are still unclear. There are potential benefits related to the use of DCB in selected populations. However, larger clinical trials with longer follow-up are still needed to confirm the enthusiastic initial results.
PURPOSE OF REVIEW: The present manuscript reviews the mechanism of action of drug-coated balloons (DCBs), offering a brief summary of the main clinical evidence on these devices. RECENT FINDINGS:DCBs are regular semi-compliant balloons coated with antiproliferative agents that are rapidly released on contact with the vessel intima, exerting an anti-restenotic effect. This technology may offer some benefits of drug-eluting stents, in particular for the treatment of restenotic lesions, small vessels, and in patients at high-bleeding risk, when the prolonged dual antiplatelet regimen should be avoided. Most recent data have pointed to a possible benefit of these devices in treating bare metal stents (BMS) or drug-eluting stents in-stent restenosis (DES ISR), effectively reducing the recurrence of restenosis and avoiding additional layers of metal in the same coronary segment. In other clinical scenarios such as bifurcations, small vessels, and de novo lesions, data is more scarce and the benefits are still unclear. There are potential benefits related to the use of DCB in selected populations. However, larger clinical trials with longer follow-up are still needed to confirm the enthusiastic initial results.
Authors: Bruno Scheller; Christoph Hehrlein; Wolfgang Bocksch; Wolfgang Rutsch; Dariush Haghi; Ulrich Dietz; Michael Böhm; Ulrich Speck Journal: N Engl J Med Date: 2006-11-13 Impact factor: 91.245
Authors: Ronald Caputo; Martin Leon; Patrick Serruys; Franz-Josef Neumann; Alan Yeung; Stephan Windecker; Jorge A Belardi; Sigmund Silber; Ian Meredith; Petr Widimský; Shigeru Saito; Laura Mauri Journal: Catheter Cardiovasc Interv Date: 2014-04-07 Impact factor: 2.692
Authors: Peter W Radke; Michael Joner; Alexander Joost; Robert A Byrne; Sonja Hartwig; Gerd Bayer; Kristin Steigerwald; Eric Wittchow Journal: EuroIntervention Date: 2011-10-30 Impact factor: 6.534
Authors: Jacques Berland; Thierry Lefèvre; Philippe Brenot; Jean Fajadet; Pascal Motreff; Patrice Guerin; Patrick Dupouy; Christian Schandrin Journal: EuroIntervention Date: 2015-12 Impact factor: 6.534
Authors: Andreas Heinrich; Martin S Engler; Felix V Güttler; Christian Matthäus; Jürgen Popp; Ulf K-M Teichgräber Journal: Sci Rep Date: 2020-10-14 Impact factor: 4.379